FTRE vs. VCYT, GH, VRDN, CDNA, RDNT, FLGT, CSTL, EXAS, JANX, and DYN
Should you be buying Fortrea stock or one of its competitors? The main competitors of Fortrea include Veracyte (VCYT), Guardant Health (GH), Viridian Therapeutics (VRDN), CareDx (CDNA), RadNet (RDNT), Fulgent Genetics (FLGT), Castle Biosciences (CSTL), Exact Sciences (EXAS), Janux Therapeutics (JANX), and Dyne Therapeutics (DYN). These companies are all part of the "medical" sector.
Veracyte (NASDAQ:VCYT) and Fortrea (NASDAQ:FTRE) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, profitability, dividends, valuation, analyst recommendations, media sentiment, risk, earnings and community ranking.
Fortrea has a net margin of -4.11% compared to Fortrea's net margin of -18.16%. Veracyte's return on equity of 4.76% beat Fortrea's return on equity.
In the previous week, Fortrea had 20 more articles in the media than Veracyte. MarketBeat recorded 23 mentions for Fortrea and 3 mentions for Veracyte. Fortrea's average media sentiment score of 1.45 beat Veracyte's score of 0.48 indicating that Veracyte is being referred to more favorably in the media.
Veracyte received 423 more outperform votes than Fortrea when rated by MarketBeat users. Likewise, 72.93% of users gave Veracyte an outperform vote while only 47.06% of users gave Fortrea an outperform vote.
Veracyte presently has a consensus target price of $27.50, indicating a potential upside of 24.89%. Fortrea has a consensus target price of $35.57, indicating a potential upside of 34.94%. Given Veracyte's stronger consensus rating and higher possible upside, analysts plainly believe Fortrea is more favorable than Veracyte.
Fortrea has higher revenue and earnings than Veracyte. Veracyte is trading at a lower price-to-earnings ratio than Fortrea, indicating that it is currently the more affordable of the two stocks.
Summary
Fortrea beats Veracyte on 11 of the 16 factors compared between the two stocks.
Get Fortrea News Delivered to You Automatically
Sign up to receive the latest news and ratings for FTRE and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding FTRE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
